Amgen has invested $66m in genetic sequencing system provider Oxford Nanopore, increasing its latest funding round to $206m.

Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.

Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.

The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

Karolinska Institute spinout Palette Life Sciences will add three medical products based on Nestlé’s intellectual property to its existing program targeting pain suffered during gynaecological procedures.

Mercia Technologies has returned to back Locate Bio's pursuit of orthopaedic therapies based on research at University of Nottingham.

The cell biology technology developer took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang Insurance are in line for exits as Innovent Biologics gears up for an initial public offering sized at $400m to $500m.

Taiho Ventures, launched two years ago with $50m in capital, has had its reserves expanded by a further $250m as Taiho Pharmaceuticals looks to enhance its open innovation work.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.